Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.42 |
| ▸ | CALCR | P30988 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922808 | 1.00 | APLNR (0.49) | APLNRMAPK8MAPK9MAPK10REN | |
| SCHEMBL22019459 | 1.00 | APLNR (0.49) | APLNRMAPK8MAPK9MAPK10REN | |
| SCHEMBL22380787 | 0.98 | APLNR (0.47) | APLNRMAPK8MAPK9MAPK10REN | |
| SCHEMBL22019186 | 0.98 | APLNR (0.47) | APLNRMAPK8MAPK9MAPK10KDM1A | |
| SCHEMBL22018355 | 0.93 | MAPK8 (0.50) | MAPK8MAPK9MAPK10KDM1ARAMP3 | |
| SCHEMBL22018549 | 0.91 | APLNR (0.49) | APLNRNAA50RAMP3CALCR | |
| SCHEMBL30933093 | 0.91 | APLNR (0.49) | APLNRNAA50RAMP3CALCR | |
| SCHEMBL30933143 | 0.91 | APLNR (0.53) | APLNRRENNAA50RAMP3CALCR | |
| SCHEMBL30933156 | 0.91 | APLNR (0.53) | APLNRRENNAA50RAMP3CALCR | |
| SCHEMBL30170451 | 0.91 | APLNR (0.53) | APLNRRENNAA50RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | claimed |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| WO-2021191689-A2 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2021-09-30 | — | — | WO | disclosed |
| US-20210024577-A1 | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT | YUYU PHARMA, INC. (KR) | 2021-01-28 | — | — | US | disclosed |
| US-20200270306-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2020-08-27 | — | — | US | disclosed |
| WO-2020099925-A2 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | APLNR 85/4885MAPK8 2678/4885MAPK9 1074/4885 |
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | APLNR 90/4885MAPK8 2755/4885MAPK9 2634/4885 |
| US-20210024577-A1 | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT | VIP, NGLY1, PROKR1 | APLNR 279/4885MAPK8 3541/4885MAPK9 1969/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | APLNR 334/4885MAPK8 3503/4885MAPK9 1766/4885 |
| US-20200270306-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | APLNR 85/4885MAPK8 2678/4885MAPK9 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.